EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 3.0

Secondary antibody deficiency and immunoglobulin replacement

Philip H. Li, Chak-Sing Lau

Hong Kong Bulletin on Rheumatic Diseases · 2017

DOI: 10.1515/hkbrd-2017-0001 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Hong Kong Bulletin on Rheumatic Diseases, 2017. Verfasst von Philip H. Li und 1 weiteren Autor:innen. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 3.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antibody deficiencies can be either primary or secondary, leading to significant morbidity and mortality without appropriate management. Secondary antibody deficiency can be due to various diseases or iatrogenic causes, especially with the use of immunosuppressive agents such as B-cell depleting therapies. Unlike its primary counterpart, little is known regarding the management of secondary antibody deficiency and it remains an underappreciated entity. This is a growing concern with the growing numbers of patients on various immunosuppressant therapies and increasing survivors of autoimmune diseases and haematological malignancies. In this report, we review the diagnosis and management of secondary antibody deficiency, especially after rituximab-induced hypogammaglobulinemia.

Zitieren

APA

Li, P. H., & Lau, C. (2017). Secondary antibody deficiency and immunoglobulin replacement. Hong Kong Bulletin on Rheumatic Diseases. https://doi.org/10.1515/hkbrd-2017-0001

Vancouver

Li PH, Lau C. Secondary antibody deficiency and immunoglobulin replacement. Hong Kong Bulletin on Rheumatic Diseases. 2017. doi:10.1515/hkbrd-2017-0001

BibTeX
@article{Li2017,
  author = {Li, Philip H. and Lau, Chak-Sing},
  title = {Secondary antibody deficiency and immunoglobulin replacement},
  journal = {Hong Kong Bulletin on Rheumatic Diseases},
  year = {2017},
  doi = {10.1515/hkbrd-2017-0001}
}
Kostenlos starten →